Phase I for Acorda's new mechanism of action in heart failure justifies more studies
15:41 EST 8 Mar 2013 | SCRIP
Phase I data are sufficient to justify another human clinical trial in the treatment of heart failure with Acorda Therapeutics' glial growth factor 2 (GGF2), which offers a new mechanism of action that may improve heart function through direct....
Original Article: Phase I for Acorda's new mechanism of action in heart failure justifies more studies
More From BioPortfolio on "Phase I for Acorda's new mechanism of action in heart failure justifies more studies"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
